As a company listed on the Euronext Growth market in Paris, Europlasma undertakes to providing the financial community with regular, transparent and accessible information and in compliance with stock market regulations
Europlasma today announces its results for the six months ended June 30, 2017, which were subject to a limited review by Auditors and were approved by the Board of Directors on October 24, 2017.
On 10 October 2017, under the chairmanship of Pierre Catlin, the Extraordinary General Meeting of the Company gathered shareholders representing 30,253,122 shares (present, represented or postal votes), corresponding to 19.88% of the share capital.
The 3rd resolution regarding the conditions of issue and subscription of the BSAR C as mentioned in the text of the resolutions addressed to the registered shareholders contained material errors.
